Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics

ConditionCarcinoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorCanadian Cancer Trials Group

About this trial

The researchers doing this study are interested in doing the following:

* Biomarker research using fresh tumour tissue and normal blood cells, and if required, tumour tissue already collected. * Bio-banking for use in future research using the collected tumour tissue / blood .

Eligibility criteria

Qualifiers

Willingness to submit a blood sample for buffy-coat and at least one tumour biospecimen.

Archived formalin fixed paraffin embedded (FFPE) blocks or slides would only be collected from patients who met CAN-IMPACT-IO study criteria and underwent fresh tumour biopsy/resection following consent but had a tumour specimen deemed insufficient for WGTS. The FFPE sample may be used to provide an alternate source of tumour tissue for WGTS in such cases. Where local centre regulations prohibit submission of blocks of tumour tissue, a predetermined number of unstained slides of representative tumour tissue may substitute the tumour block.

Participant consent for the CAN-IMPACT-IO study must be appropriately obtained in accordance with applicable local and regulatory requirements.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

120 Participants
are grouped into 1 trial group

Locations

This trial has no locations

Sponsors and collaborators